PHOENIX, Oct. 12, 2018 (GLOBE NEWSWIRE) — INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that its collaboration with the Center for Medicinal Cannabis Research (CMCR) at the University of California (UC) San Diego School of Medicine has added a third study.
This additional study will evaluate the pharmacological effects of cannabidiol (CBD) oral solution from INSYS on anxiety associated with anorexia nervosa in adult patients. The previous two collaborative CMCR studies, announced earlier this year, will focus on CBD in the treatment of severe symptoms of autism in pediatric patients and early psychosis in adult patients. The IND (investigational new drug) application for the autism study is on track for filing in the fourth quarter of 2018.
Separately, INSYS has initiated three clinical trials of its CBD oral solution—for childhood absence epilepsy (Phase 2),
... read more at: https://www.apnews.com/c55e9288830313466bf26e91b0af87eb